1. Home
  2. UA vs BLLN Comparison

UA vs BLLN Comparison

Compare UA & BLLN Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo Under Armour Inc. Class C

UA

Under Armour Inc. Class C

HOLD

Current Price

$6.46

Market Cap

3.4B

ML Signal

HOLD

BLLN

BillionToOne Inc.

N/A

Current Price

$85.02

Market Cap

3.7B

Sector

Health Care

ML Signal

N/A

Company Overview

Basic Information
Metric
UA
BLLN
Founded
1996
2016
Country
United States
United States
Employees
14400
713
Industry
Apparel
Medical Specialities
Sector
Consumer Discretionary
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
3.4B
3.7B
IPO Year
N/A
N/A

Fundamental Metrics

Financial Performance
Metric
UA
BLLN
Price
$6.46
$85.02
Analyst Decision
Buy
Analyst Count
0
7
Target Price
N/A
$126.71
AVG Volume (30 Days)
2.4M
343.3K
Earning Date
05-12-2026
05-06-2026
Dividend Yield
N/A
N/A
EPS Growth
N/A
N/A
EPS
N/A
N/A
Revenue
N/A
N/A
Revenue This Year
N/A
$45.96
Revenue Next Year
$1.57
$30.11
P/E Ratio
N/A
N/A
Revenue Growth
N/A
N/A
52 Week Low
$3.95
$61.96
52 Week High
$7.91
$138.70

Technical Indicators

Market Signals
Indicator
UA
BLLN
Relative Strength Index (RSI) 60.60 56.31
Support Level $6.24 $79.33
Resistance Level $7.08 $98.48
Average True Range (ATR) 0.25 6.98
MACD 0.10 0.16
Stochastic Oscillator 96.67 60.08

Price Performance

Historical Comparison
UA
BLLN

About UA Under Armour Inc. Class C

Under Armour develops, markets, and distributes athletic apparel, footwear, and accessories in North America, Asia-Pacific, Europe, and Latin America. Consumers of its performance-based clothing and shoes include professional and amateur athletes, sponsored college and professional teams, and people with active lifestyles. The company sells merchandise through wholesale partners, company-owned digital channels, and approximately 450 company-owned outlet and full-price stores. The Baltimore-based firm was founded in 1996 and is led by controlling shareholder Kevin Plank.

About BLLN BillionToOne Inc.

BillionToOne Inc is a molecular diagnostics company. It offers a portfolio of ultrasensitive tests covering prenatal genetic testing, cancer therapy selection, and response monitoring, which are based on its Quantitative Counting Templates (QCT) molecular counting platform. The company's product portfolio comprises UNITY, a portfolio of prenatal testing products that can conduct fetal risk analysis without requiring a paternal sample; Northstar Select, a ultrasensitive liquid biopsy test that provides insights into appropriate therapies for stage III or IV cancer patients; and Northstar Response, a tissue-free, pan-cancer, liquid biopsy test that measures several genomic loci uniquely methylated in cancer to provide insight into dynamic changes in therapy response.

Share on Social Networks: